Back To Search Instructions
Protocols
20 protocols meet the specified criteria
Disease Site: Breast - Female
Protocol No.TitleStatus
1200000138Biospecimen Repository for Individuals at High Risk for Breast, Ovarian, or Other Hereditary CancersOpen
1300000027S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapyOpen
1300000153Investigating DNA repair mechanisms, hypoxia and hypoxia signaling pathway markers in breast cancer patientsOpen
1300000596Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer RiskOpen
1300000688A retrospective review of patients receiving concurrent capecitabine and radiation therapy for high risk breast cancerOpen
1312169608Phase II Trial of Metronomic Eribulin (Halaven) In Pretreated Metastatic Breast Cancer (MBC)Open
1403248464Alliance A011106 ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III StudyOpen
1408442431A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft® Axxent® eBx System at the Time of Breast Conservation Surgery for Early Stage Breast CancerOpen
1604536433A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose- Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable CancersOpen
1606619215An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast CancerOpen
1612074879An Open-Label, Multicenter, Dose Escalation, Phase IA/IB Study to Evaluate Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281, an Immunocytokine Consisting of Interleukin 2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Alpha (FAP), as a Single Agent (Part A) or in Combination with Trastuzumab or Cetuximab (Part B or C)Open
1612084235A Phase 3 Open-Label, Randomized, Multicenter Study Of Nktr-102 Versus Treatment Of Physician¿s Choice (Tpc) In Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases And Have Been Previously Treated With An Anthracycline, A Taxane, And CapecitabineOpen
1703269356S1418: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy.Open
1704374063A Phase 1 Open-Label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer SubjectsOpen
1704390293A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant TumorsOpen
1706546860A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment with Checkpoint Inhibitors (CPI) or Triple Negative Breast Cancer (TNBC) Failing Front-line Chemotherapy for Metastatic DiseaseOpen
1707616299A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without SurgeryOpen
1707634514Evaluating the role of diffusion tensor imaging in predicting development of chemotherapy induced peripheral neuropathy in patients with breast cancerOpen
PHXA-15-0013-10-15S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy Open
PHXE-16-0167-10-15A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant ChemotherapyOpen